Literature DB >> 1836684

Pharmacokinetic analysis of the monoclonal antibody A7-neocarzinostatin conjugate administered to nude mice.

K Kitamura1, T Takahashi, A Noguchi, H Tsurumi, K Takashina, J Okuzumi, T Yamaguchi.   

Abstract

The pharmacokinetics of a disulfide linked conjugate of a murine monoclonal antibody A7 with neocarzinostatin (A7-NCS) was studied following its intravenous administration to nude mice. Disappearance of the conjugate from the circulation was biphasic: an early rapid phase was followed by a much slower phase. The conjugate was removed from the blood circulation with a half-life of 12 hr, showing nearly the same kinetics as the free antibody. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis showed that the disulfide linkage in A7-NCS was stable at least for 48 hr after administration of the conjugate to nude mice. The conjugate concentration in a human colon cancer SW1116 derived tumor reached maximum at 24 hr after injection and remained high for an additional 24 hr. The passive hemagglutination inhibition assay revealed that NCS in the conjugated form can be efficiently delivered to the target tissue. The present report indicates that A7-NCS was sufficiently stable in circulation to reach the target tumor without releasing NCS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836684     DOI: 10.1620/tjem.164.203

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  Fate of antibody-neocarzinostatin conjugates bound to human colonic carcinoma cells in vitro.

Authors:  T Yokota; T Yamaguchi; K Kitamura; T Takahashi
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

2.  Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study.

Authors:  K Yamamoto; K Kitamura; S Nishida; D Ichikawa; K Okamoto; T Yamaguchi; T Takahashi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.

Authors:  Yumei Xie; Taryn R Bagby; M S Cohen; M Laird Forrest
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

4.  The role of monoclonal antibody A7 as a drug modifier in cancer therapy.

Authors:  K Kitamura; T Miyagaki; N Yamaoka; H Tsurumi; A Noguchi; T Yamaguchi; T Takahashi
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  Efficacy and specificity of a monoclonal antibody-drug conjugate in chemotherapy by intratumoral injection.

Authors:  K Kitamura; T Takahashi; T Miyagaki; N Yamaoka; H Tsurumi; E Ohtsuji; M Kamiguchi; A Noguchi; T Yamaguchi
Journal:  Jpn J Cancer Res       Date:  1992-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.